title: Tyrosine phosphorylation of the kappa -opioid receptor regulates agonist efficacy.
abstract: To explore the role of highly conserved tyrosine residues in the putative cytoplasmic domains of the seven-transmembrane G protein-coupled opioid receptors, we expressed the rat kappa-opioid receptor (KOR) in Xenopus oocytes and then activated the intrinsic insulin receptor tyrosine kinase. KOR activation by the agonist produced a strong increase in potassium current through coexpressed G protein-gated inwardly rectifying potassium channels (K(IR)3). Brief pretreatment with insulin caused a 60% potentiation of the KOR-activated response. The insulin-induced increase in kappa-opioid response was blocked by the tyrosine kinase inhibitor genistein. In contrast, insulin had no effect on the basal activity of K(IR)3, suggesting that KOR is the target of the tyrosine kinase cascade. Mutation of tyrosine residues to phenylalanines in either the first or second intracellular loop of KOR to produce KOR(Y87F) and KOR(Y157F) had no effect on either the potency or maximal effect of. However, neither KOR(Y87F)- nor KOR(Y157F)-mediated responses were potentiated by insulin treatment. Insulin pretreatment shifted the dose-response curve for activation of KOR by increasing the maximal response without changing the EC(50) value for. These results suggest that insulin increases the efficacy of KOR activation by phosphorylating two tyrosine residues in the first and second intracellular loops of the receptor. Thus, tyrosine phosphorylation may provide an important mechanism for modulation of G protein-coupled receptor signaling.
authors.affiliation: Department of Pharmacology and the Neurobiology Program, University of Washington, Seattle, Washington 98195-7280, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Appleyard
authors.forename: J P
authors.initials: JP
authors.lastname: McLaughlin
authors.forename: C
authors.initials: C
authors.lastname: Chavkin
mesh_terms: D000595:Amino Acid Sequence; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D044482:Benzeneacetamides; D002478:Cells, Cultured; D005260:Female; D019833:Genistein / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009865:Oocytes / Q000502:physiology; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism*; D017433:Protein Structure, Secondary; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017473:Receptors, Opioid, kappa / Q000819:agonists* / Q000737:chemistry / Q000235:genetics; D011994:Recombinant Proteins / Q000819:agonists / Q000737:chemistry; D014982:Xenopus laevis
chemical_list: D000700:Analgesics; D044482:Benzeneacetamides; D007328:Insulin; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D011994:Recombinant Proteins; D019000:Phosphotyrosine; D019833:Genistein; C045444:U 69593